Effect of introduction of an Arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors

This publication has 23 references indexed in Scilit:

• Properties of Chimeric Secretin and VIP Receptor Proteins Indicate the Importance of the N-Terminal Domain for Ligand Discrimination
  Biochemical and Biophysical Research Communications, 1995
• Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells
  European Journal of Pharmacology: Molecular Pharmacology, 1995
• The VIP₂ receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide
  FEBS Letters, 1993
• Cloning of a Splice Variant of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Type I Receptor
  Biochemical and Biophysical Research Communications, 1993
• Solution structure of pituitary adenylate cyclase activating polypeptide by nuclear magnetic resonance spectroscopy
  Biochemistry, 1993
• Structural requirements for the occupancy of pituitary adenylate‐cyclase‐activating‐peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB‐OK‐1 cell membranes
  European Journal of Biochemistry, 1992
• Solution structure of an analog of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics
  Biochemistry, 1989
• Secretin Receptors in Human Pancreatic Membranes
  Pancreas, 1988
• A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29
  Peptides, 1986
• Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: Effect of nine partial sequences
  Biochemical and Biophysical Research Communications, 1984